Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 May 29;19(2):727-734.
doi: 10.1007/s40200-020-00553-w. eCollection 2020 Dec.

Comparison of EWGSOP-1and EWGSOP-2 diagnostic criteria on prevalence of and risk factors for sarcopenia among Iranian older people: the Bushehr Elderly Health (BEH) program

Gita Shafiee  1 , Ramin Heshmat  1 , Afshin Ostovar  2 , Fatemeh Khatami  1 , Noushin Fahimfar  2 , Seyed Masoud Arzaghi  3 , Safoora Gharibzadeh  2 , Sara Hanaei  4   5 , Iraj Nabipour  6 , Bagher Larijani  7
Affiliations

Comparison of EWGSOP-1and EWGSOP-2 diagnostic criteria on prevalence of and risk factors for sarcopenia among Iranian older people: the Bushehr Elderly Health (BEH) program

Gita Shafiee et al. J Diabetes Metab Disord. .

Abstract

Background: This study proposed to compare the prevalence and risk factors for sarcopenia by EGWSOP-1 and EWGSOP-2 diagnostic criteria in Iran.

Methods: This cross-sectional study was conducted based on the data collected during the Bushehr Elderly Health (BEH) Program, stage II. Sarcopenia was defined as 3 definitions: EWGSOP-1(with Iranian cut off), EWGSOP-2(with Iranian cut off), EWGSOP-2(with European cut off) definition. We evaluated the age-standardized prevalence of sarcopenia in both genders. Regression analysis was used to show the associations in the adjusted models.

Results: Among 2426 participants, age-standardized prevalence of sarcopenia, and severe sarcopenia by EWGSOP-1 were 19.7%, and 12.9%, in men and 13.6%, and 16.7% in women, respectively. When we used EWGSOP-2 (with Iranian cut-off) criteria, these values were 10.5%, and 12.7% among men and 7.13% and 16.5% in women, respectively. The prevalence sarcopenia and severe sarcopenia by EWGSOP-2 (with European cut-off) were 12.7%, and 13.4% in men and 5.42%, and 13.7% in women, respectively. In both genders, getting older and high-fat mass were positively associated with sarcopenia, and BMI had a significant inverse association in both genders and all defintions.

Conclusions: Results showed that a prevalence of sarcopenia varied largely by using different criteria, in both sexes. EWGSOP2- defined sarcopenia prevalence was lower than that defined using EWGSOP-1 criteria due to different diagnostic factors to detect sarcopenia. Some adverse outcomes should be considered for evaluating sarcopenia to compare the accuracy of EWGSOP-1 and EWGSOP-2.

Keywords: EWGSOP-1; EWGSOP-2; Prevalence; Sarcopenia.

PubMed Disclaimer

Conflict of interest statement

Conflict of interestGita Shafiee, Ramin Heshmat, Afshin Ostovar, Fatemeh Khatami, Noushin Fahimfar, Seyed Masoud Arzaghi, Safoora Gharibzadeh, Sara Hanaei, Iraj Nabipour, Bagher Larijani declare that they have no conflict of interest.

Figures

Fig. 1
Fig. 1
Age-standardized prevalence rates of sarcopenia according to different definitions in both genders
See this image and copyright information in PMC

References

    1. Cruz-Jentoft A, European Working Group on Sarcopenia in Older People Sarcopenia: European consensus on definition and diagnosis. Report of the European Workign Group on Sarcopenia in Older People. Age Ageing. 2010;39:412–23. doi: 10.1093/ageing/afq034. - DOI - PMC - PubMed
    1. Cruz-Jentoft AJ, Bahat G, Bauer J, Boirie Y, Bruyere O, Cederholm T, et al. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing. 2019;48(4):601. doi: 10.1093/ageing/afz046. - DOI - PMC - PubMed
    1. Shafiee G, Keshtkar A, Soltani A, Ahadi Z, Larijani B, Heshmat R. Prevalence of sarcopenia in the world: a systematic review and meta- analysis of general population studies. Journal of diabetes metabolic disorders. 2017;16:21. doi: 10.1186/s40200-017-0302-x. - DOI - PMC - PubMed
    1. von Haehling S, Morley JE, Anker SD. An overview of sarcopenia: facts and numbers on prevalence and clinical impact. J Cachexia Sarcopenia Muscle. 2010;1(2):129–33. doi: 10.1007/s13539-010-0014-2. - DOI - PMC - PubMed
    1. Fielding RA, Vellas B, Evans WJ, Bhasin S, Morley JE, Newman AB, et al. Sarcopenia: an undiagnosed condition in older adults. Current consensus definition: prevalence, etiology, and consequences. International working group on sarcopenia. J Am Med Dir Assoc. 2011;12(4):249–56. doi: 10.1016/j.jamda.2011.01.003. - DOI - PMC - PubMed

LinkOut - more resources